Journal articleCurr Treat Options Oncol2021
Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations.
- Journal
- Curr Treat Options Oncol
- Published
- 12 January 2021
- Citations
- 14
These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
abstract license unknown
Opinion statement Due to its immunosuppressive tumor microenvironment, prostate cancer has historically been difficult to treat with immuno-oncology approaches. Other than pembrolizumab, which is now regulatory-approved for all microsatellite instability (MSI)-high and tumor mutational burden (TMB)-high advanced solid tumors, sipuleucel-T is the only immunotherapeutic agent approved by the US Food and Drug Administration (FDA) for prostate cancer. … Excerpt only: this text is the publisher’s. Read it in full at the source.